Personalized Intervention Program: Tobacco Treatment for Patients at Risk for Lung Cancer

被引:5
|
作者
Bold, Krysten W. [1 ]
Toll, Benjamin A. [1 ,2 ,3 ]
Cartmel, Brenda [4 ]
Ford, Bennie B. [1 ]
Rojewski, Alana M. [2 ,3 ]
Gueorguieva, Ralitza [1 ,4 ]
O'Malley, Stephanie S. [1 ,5 ]
Fucito, Lisa M. [1 ,5 ,6 ]
机构
[1] Yale Sch Med, New Haven, CT USA
[2] Med Univ South Carolina, Charleston, SC 29425 USA
[3] Hollings Canc Ctr, Charleston, SC USA
[4] Yale Sch Publ Hlth, New Haven, CT USA
[5] Yale Canc Ctr, New Haven, CT USA
[6] Smilow Canc Hosp Yale New Haven, New Haven, CT USA
来源
JOURNAL OF SMOKING CESSATION | 2018年 / 13卷 / 04期
基金
美国国家卫生研究院;
关键词
D O I
10.1017/jsc.2017.24
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: Lung cancer screening and tobacco treatment for patients at high-risk for lung cancer may greatly reduce mortality from smoking, and there is an urgent need to improve smoking cessation therapies for this population.Aims: The purpose of this study is to test the efficacy of two separate, sequential interventions to promote tobacco cessation/reduction compared to standard care in smokers considered high-risk for lung cancer.Methods: The study will recruit 276 current smokers attending a lung cancer screening clinic or considered high-risk for lung cancer based on age and smoking history across two sites. Patients first will be randomized to either standard tobacco treatment (8 weeks of nicotine patch and five individual counselling sessions) or standard tobacco treatment plus personalized gain-framed messaging. At the 8-week visit, all patients will be re-randomized to receive biomarker feedback or no biomarker feedback. Repeated assessments during treatment will be used to evaluate changes in novel biomarkers: skin carotenoids, lung function, and plasma bilirubin that will be used for biomarker feedback. We hypothesize that personalized gain-framed messages and receiving biomarker feedback related to tobacco cessation/reduction will improve quit rates and prevent relapse compared to standard care. Primary outcomes include 7-day point-prevalence abstinence verified with expired carbon monoxide at 8 weeks and mean cigarettes per day in the past week at 6 months.Conclusions: Study findings will inform the development of novel interventions for patients at risk for lung cancer to improve smoking cessation rates.
引用
收藏
页码:244 / 247
页数:4
相关论文
共 50 条
  • [31] Personalized treatment options for Patients with colorectal cancer
    Lenz, Heinz-Josef
    TUMOR BIOLOGY, 2012, 33 : 60 - 60
  • [32] Primary and Secondary Prevention of Lung Cancer: Tobacco Treatment
    Kathuria, Hasmeena
    Neptune, Enid
    CLINICS IN CHEST MEDICINE, 2020, 41 (01) : 39 - +
  • [33] Tobacco Assessment in Completed Lung Cancer Treatment Trials
    Peters, Erica N.
    Warren, Graham W.
    Sloan, Jeff A.
    Marshall, James R.
    CANCER, 2016, 122 (21) : 3260 - 3262
  • [34] Personalized treatment of severe pneumonia in cancer patients
    Rabello, Ligia S. C. F.
    Lisboa, Thiago
    Soares, Marcio
    Salluh, Jorge I. F.
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2015, 13 (11) : 1319 - 1324
  • [35] Application of Radiomics for Personalized Treatment of Cancer Patients
    Meng, Yiming
    Sun, Jing
    Qu, Na
    Zhang, Guirong
    Yu, Tao
    Piao, Haozhe
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 10851 - 10858
  • [36] Detection of plasma EGFR mutations for personalized treatment of lung cancer patients without pathologic diagnosis
    Deng, Qinfang
    Fang, Qiyu
    Sun, Hui
    Singh, Aditi P.
    Alexander, Mariam
    Li, Shenduo
    Cheng, Haiying
    Zhou, Songwen
    CANCER MEDICINE, 2020, 9 (06): : 2085 - 2095
  • [37] Evaluation of a Personalized Subcutaneous Immunoglobulin Treatment Program for Neurological Patients
    Suleman, Adam
    Theoret, Lynda
    Bourque, Pierre
    Pringle, Elizabeth
    Cameron, D. William
    Cowan, Juthaporn
    CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2019, 46 (01) : 38 - 43
  • [38] Association of the California tobacco control program with declines in lung cancer incidence
    Barnoya, J
    Glantz, S
    CANCER CAUSES & CONTROL, 2004, 15 (07) : 689 - 695
  • [39] Clinic utilization and smoking cessation practices among ethnic minority patients referred for paired lung cancer screening and tobacco treatment services at a community cancer program
    Akindele, Ruth N.
    Svoboda, Ludmila A.
    Gonzalez, Sabrina G.
    Lathan, Christopher S.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2017, 26 (02)
  • [40] Association of the California Tobacco Control Program with Declines in Lung Cancer Incidence
    Joaquin Barnoya
    Stanton Glantz
    Cancer Causes & Control, 2004, 15 : 689 - 695